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ABSTRACT
Targeted drug delivery has been the major topic in drug formulation and delivery. As
nanomedicine emerges to create nano-scale therapeutics and diagnostics, it is still
essential to embed targeting capability to these novel systems to make them useful.
Design of robust nanomedicine with universal targeting capabilities could provide
effective solutions to the ever increasing demand of curing and preventing major
diseases.
Diseases like carcinoma & ischemia are accompanied with hypoxia and acidosis.
Because of the elevated glycolysis and acidosis in the diseased cells, they show a
lower pH in the surface of the cells which promotes the appearance of aggressive
malignant cells with enhanced multidrug resistance. Therefore, the extracellular
acidity can be used as a hallmark to target and deliver nanotheranostics. Thus coating
nanoparticles with pH (Low) Insertion Peptides (pHLIPs) increase efficiency of
targeting acidic diseased tissues. This novel method could be used as a promising
method to create future nanotheranostics for cancer and other diseases which are
dominating the present world.
The main goal of the work presented here is to


Review the field of advanced targeted nanomedicine and its future trends;



Design pHLIP® coated lipid & surfactant based nanovesicles to deliver
therapeutic and diagnostic agents;



Use different drugs and dyes for imaging and therapy ;



Assess the cytotoxicity, targeting capabilities and the cellular interaction of
these nanovesicles in in- vitro and in-vivo.
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PREFACE
This dissertation is written in the ‘Manuscript Format’ using the Thesis/ Dissertation
template of the University of Rhode Island. There are three manuscripts, each organized
into a chapter. The tables and figures of each manuscript are listed under the
corresponding chapter in the list of tables and figures.
The results of my studies presented here were published in three papers:
1.

Pereira, Mohan C, Yana K. Reshetnyak, and Oleg A. Andreev. "Advanced
targeted nanomedicine." Journal of biotechnology 202 (2015):

2.

Wijesinghe, D., Pereira, Mohan C., Lu, A., Reshetnyak, Y. K., & Andreev, O.
A. “pH dependent transfer of nano-pores into membrane of cancer cells to induce
apoptosis.” Scientific reports, 3 (2013):

3.

Pereira, M.C., Monica, P., Carafa, M., Andreev O.A., Reshetnyak, Y.K. Novel
pHLIP coated niasomes for diagnostic and therapy, in preparation

Work was presented on the following 3 Meetings/Conferences:
“Formulation and Delivery of Lipophilic Drugs to Cancer Cells by pHLIP® coated
Liposomes”, World Medical Nanotechnology Congress & Expo, Dallas, TX (2016)
“pH dependent transfer of nano-pores into membrane of cancer cells to induce
apoptosis”,CHI's Biologics Formulation & Delivery Summit, Boston, MA (2014).
“pH dependent transfer of nano-pores into membrane of cancer cells to induce
apoptosis”, American Physical Society – New England section, Bridgewater, MA
(2013).
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Abstract
Targeted drug delivery has been the major topic in drug formulation and delivery. As
nanomedicine emerges to create nano scale therapeutics and diagnostics, it is still
essential to embed targeting capability to these novel systems to make them useful. Here
I discuss various targeting approaches for delivery of therapeutic and diagnostic nano
materials in view of search for more universal methods to target diseased tissues. Many
diseases are accompanied with hypoxia and acidosis. Coating nanoparticles with pH
Low Insertion Peptides (pHLIPs) increases efficiency of targeting acidic diseased
tissues. It has been showing promising results to create future nanotheranostics for
cancer and other diseases which are dominating in the present world.

Keywords: pHLIP, nanomedicine, passive targeting, active targeting, tissue acidity,
environmental targeting
Highlights
•

Nanomaterials are used to target both imaging and therapeutic agents

•

Targeting a tumor environment might better address issue of tumor
heterogeneity

•

pHLIP senses acidity on the surface of cells

•

pHLIP targets nanomaterials to acidic diseased tissue

•

pHLIP promotes cytoplasmic delivery of nanomaterial’s payloads
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1. Introduction
For a long time people have been working on developing therapeutic agents so that they
can tune pharmacological and pharmacokinetic properties to treat diseases and get
desired results. In their continuous quest for food and survival, our ancestors must have
experienced the effects of natural sources of pharmacologically active chemical
substances produced by organic and inorganic materials such as plants, fungi, insects,
animal excreta, reptiles and mineral ores for better or for worse. They must have learnt
to extract active ingredients from natural resources using crude methods and enhanced
to use as pain killers or to heal wounds or to treat all types of diseases known to them.
Ebers papyrus, dated back to ~ 1500 BC provides a detailed description of medical
treatments used by ancient Egyptians [1, 2]. In early as 7 century AD, metal, mineral
and herbal based particles called Bhashma has been used in Ayurvedic medicine in
Indian sub-continent. Modern analysis showed that these formulations contained
Fe 2 O 3 , FeS 2 , CuS and SiO 2 and also particle sizes were regulated in the range of 12 µm [3, 4]. Undoubtedly, these ancient knowledge had laid the foundation for modern
drug formulation and delivery and made a huge breakthrough in this field as the
chemical analysis became first available to us in 19th century [5 ].
While the conventional drugs are still being widely used, the innovation of therapeutic
nanoparticles has been radically changing the future of drug formulation and delivery
[6-11]. Nanoparticles are becoming more popular due to their unique tunable
physicochemical properties. They have shown promising results in delivery of variety
of molecules improving the therapeutic index of drugs by enhancing their efficacy
and/or increasing their tolerability in the body. Nano-carries could also improve the
4

bioavailability of water-insoluble drugs, carry large payloads, protect the therapeutic
agents from physiological barriers, as well as enable the development of novel classes
of bioactive macromolecules [12].
2. Targeted delivery of nanoparticles
Almost a century ago, Paul Ehrlich introduced the concept of targeted drug delivery. It
was considered as a hypothetical ‘magic bullet’ as an entity consisting of two
components — the first one should recognize and bind the target, while the second
should provide a therapeutic action in this target. Currently, the concept of ‘magic
bullet’ includes a coordinated behavior of three components – drug, targeting moiety
and pharmaceutical carrier [13]. Nanoparticles can be designed to have all three
properties of the revised version of Ehrlich’s “magic bullet”, and they could be used as
therapeutics and/or diagnostics. When designing the nano-drugs it is essential to
understand the target region. Target regions could be whole organs (heart, lung, brain,
liver and etc), tissues (muscle), cells (nerve, dendrite and etc), disease specific structures
(tumor cells) or cellular components. The efficacy of the therapeutics, effectiveness of
the diagnostics, safety, affordability and access will measure the final success of
nanoparticles in medicine in regard to its applied value to the patients.
3. Three major ways of delivery of nanoparticles
Nanoparticle drug delivery systems use the characteristics of disease tissues to
selectively target their payloads, either by passive, active or physical targeting [14, 15].
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3.1 Passive targeting
When nanoparticles localize into specific organs or site of disease via biological
mechanisms, such as RES (reticuloendothelial system) or EPR (enhanced permeability
and retention) effects, they are known as 'passive targeting agents' [16].
RES also called macrophage system or mononuclear phagocyte system, is a class of
cells which are part of the body’s defense mechanisms. If nanoparticles are not protected
against RES, they will end up in liver, spleen or lymph nodes very soon. Even though
this seems to be a disadvantage, RES mechanism can be successfully used for mapping
liver [16-21], spleen [18, 19, 22-25] and lymph nodes [17, 18, 22]. The information gain
from mapping of lymph nodes gives vital indications for cancer staging and metastatic
potential of tumor, which could prevent unnecessary dissection surgery.
The EPR effect is very common for most of the solid tumors and has been exploiting as
a passive mechanism to deliver therapeutic agents. As tumor grows its architecture of
vasculature become quite abnormal, showing lack of lymphatic drainage and leaky
blood vessels. This allows the long circulating nanoparticles to accumulate in tumor site
overtime at higher levels compared to other organs [26-34].

3.2 Active Targeting
Active targeting uses peripherally conjugated specific targeting moieties for enhanced
delivery of nanoparticles. The targeting moieties are various ligands including
antibodies, peptides, aptamers or small molecules that possess high affinity toward
unique molecular signatures found in diseased tissue to achieve active targeting [35].
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Three general categories of active targeting methods are i) angiogenesis-associated
targeting, ii) uncontrolled cell proliferation targeting and iii) tumor cell targeting.
Chemical stimulation for angiogenesis is caused by variety of proangiogenic factors
such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor
(bFGF). They are the key ingredients of this very complex biological mechanism which
is essential for life. Pathological angiogenesis or abnormally rapid proliferation of blood
vessels is common for growth of solid tumors. Therefore the targeting of angiogenesis
has become a focus for cancer therapeutics [34, 36-42]. Thus, the growth factors are
attacked by inhibitors of angiogenesis to regulate the tumor progression [43, 44].
Another significant target for cancer cells are the cell proliferation markers. These
markers are not unique to cancer cells but they are overexpressed in certain cancer cells.
The human epidermal receptors (HER), transferrin receptors and folate receptors are
widely being employed.

Actively targeting nanoparticles have been using the

monoclonal antibodies to target overexpressed cell proliferation receptors [35, 45-48].
According to the American Cancer Society statistics, in US, it is estimated that more
than 1.6 million new cases of cancer will be diagnosed and more than 0.5 million cancer
deaths will occur in 2014. The four most common types of cancers that will be
diagnosed in 2014 in the United States are breast in women and prostate in men, lung,
and colorectal. Therefore targeting of specific tumor cells is becoming another popular
area. FDA has already approved several monoclonal antibodies for the treatment of
specific types of cancers. Trastuzumab, a humanized monoclonal antibody against
HER-2 which is overexpressed in human breast cancer, for the treatment of HER-2positive metastatic breast cancer was introduced in 1998. Panitumumab, a human
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antibody against EGFR produced in transgenic mice (XenoMouse), for the treatment of
EGFR-positive colorectal cancer was approved in 2006. Avastin, a humanized antibody
against VEGF, for the treatment of metastatic colorectal cancer was introduced in 2004.
Cetuximab, a chimeric antibody directed to EGFR (HER-1) for the treatment of
advanced colorectal cancer appeared in 2004. Avastin® (Genentech, South San
Francisco, CA) is a recombinant humanized anti-VEGF monoclonal antibody for the
treatment of non-small cell lung cancer, metastatic colorectal cancer and metastatic
breast cancer were approved [35].
The major advantage of the active targeting over the passive targeting is a selective
delivery of nanoparticles to the specific tumors/pathogenic tissues, which remain in the
site of disease for an extended period of time, thereby increasing the local accumulation
of the nanoparticles in the sites of interest. [49-52]. However, the heterogeneity and
adaptability of cancers are difficult to overcome, which makes it problematic to create
a common cure based on active targeting. Therefore, it is important to identify a
universal hallmark for majority of cancers or consider use of external physical stimuli
as a targeting strategy.
3.3 Physical Targeting
In many cases, pathological area differs from normal tissues in certain physical
properties, such as temperature, lack of oxygen and pH. These natural properties are
common for majority of cancers independent of origin, and could be exploited as
targeting approaches. The principle behind use of nanoparticles for physical targeting is
that a stimulus, which may be applied externally or originate within the pathological
site, induces either a physical change in the structure of the nanoparticle itself, thereby
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causing the eradication of the target or modulating the rate at which an embedded drug
is released. pH, lack of oxygen, temperature, ultrasound, electromagnetic radiation and
mechanical forces serve as stimuli for physical targeting.

3.3.1

Magnetic-sensitive systems

Use of magnetic sensitive nanoparticles was first proposed by Widder, Senyi and their
colleagues in late 1970s [53, 54]. These nanoparticles are primarily fabricated in such
way that therapeutic agents are attached to, or encapsulated within, a magnetic core or
shell by giving capability of functionalizing their surfaces. Once functionalized, the
nanoparticles are injected into the bloodstream, often using a catheter to position the
injection site near the target. Powerful rare earth magnets are focused over the target
site to apply magnetic fields with high-gradient and the forces affecting the particles.
So, the field permits nanoparticles to be captured and released at the target. Clinical
trials done by Koda et al. to deliver doxorubicin hydrochloride showed great deal of
success for hepatocellular carcinoma [55]. This method may be effective for targets
close to the body’s surface, but as the magnetic field strength falls off rapidly with
distance, sites deeper within the body become more difficult to target [56]. Several
groups recently proposed a way to overcome this hurdle by implanting magnets near the
target site, within the body [57, 58]. However, this method is invasive and not
systematic, which apply significant restrictions for clinical use. Moreover this method
would not target metastases, which make cancer a lethal disease.
Key advantages of magnetic NPs are they can be (i) visualized (super paramagnetic NPs
are used in MRI);[59, 60] (ii) guided or held in place by means of a magnetic field; (iii)
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heated in a magnetic field to trigger drug release or to produce hyperthermia/ablation
of tissue; (iv) targeted specific locations in the body; (v) reduced the quantity of drug
needed to attain a particular concentration in the vicinity of the target; (vi) reduced of
the concentration of the drug at non target sites minimizing severe side effects and (vii)
used to perform magnetic guided surgeries for surgically impossible tumors either due
to too hemorrhagic or localized in tissues with high risk of healthy tissue injury.
Despite of these advantages they also inherit limitations. MNPs accumulate throughout
the cross section from the external source to the depth marking the effective field limit
which is a drawback. Magnetic agglomeration at the absence of magnetic field is tackled
by superparamagnetic NPs. Creation of smaller NPs, is essential to achieve superparamagnetism. As the size becomes smaller, particles’ response to the magnetic field
is remarkably reduced. As a result of that it makes difficult to direct particles and keep
them in the proximity of the target while withstanding the drag of blood flow.
3.3.2

Ultrasound-sensitive systems

When nanoparticles are used to target solid tumors, homogeneous distribution of most
of them in tumor is always questionable. Although nanoparticles can extravasate from
the blood to the extracellular matrix, they do not always travel far away from the blood
vessels. Thus, only a small population of cancer cells located close to the blood vessels
will be exposed to the cytotoxic drugs thus minimizing it’s therapeutic index. As
nanoparticles stay for longer periods of time, they could target and bring harm to normal
tissues. Researchers have explored ways to use ultrasound to enhance the cellular uptake
of nanoparticles in the target sites by increasing the permeability of the capillary walls,
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pushing them through the extracellular matrix, enhancing the release of the drug from
the nanoparticles and improving the cellular uptake.
Escoffre and his colleagues showed on 2D and 3D in vitro models that the focusedultrasound not only helps nanoparticles to penetrate into the interior of the tumor, it
also helps to release drugs to the intercellular space without altering chemical properties
[61-64]. The use of phenomenon of cavitation, which is the formation of bubbles in a
medium exposed to intense focused ultrasound to disrupt the targeted tissue, is another
application of this kind. Microbubble-based drug-delivery vehicles can flow through the
vasculature into the ultrasound focal zone within the tumor region and they can release
payloads upon the rupture. These bubbles can be also used as imaging contrast agents
to improve diagnosis and detection of cancer [65-69].
Non-invasiveness, the absence of ionizing radiations, and the facile regulation of tissue
penetration depth by tuning frequency, duty cycles and time of exposure can be
identified as the main advantages of using ultrasound sensitive systems [70].
Ultrasound can trigger release of drugs from various nanocarriers by destabilization.
Ultrasound triggered delivery systems has the ability to release drugs into cytosol as
result of pore formation in the cell membrane. Therefore they can bypass degenerative
endocytotic pathway which is especially useful in DNA transfection [71]. Low
frequency ultrasounds can be used to promote the delivery of some liposomal based
drugs through the skin to inhibit progression of melanocytic lesions[72]. However, the
increased vessel permeability through ultrasound can also impact negatively by
promoting metastatic dissemination. Possible metastatic dissemination can be
minimized by using NPs containing agents, which are able to efficiently interact with
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ultrasonic waves and decrease the threshold frequencies of ultrasound waves.
Effectiveness of microbubbles based drug delivery for tissue targeting may be limited
by their short lifespan and absence of extravasation. The development of
perfluorocarbon (PFC) nanoemulsions and PFC droplets functionalized with aptamers,
which can be converted into microbubbles under therapeutic ultrasounds have
significantly improved cellular uptake and/or release of drugs in tumor sites[73].
3.3.3

Temperature-sensitive systems

Above we gave examples of external stimuli applied to diseased area to enhance
delivery of nanoparticles and/or release of imaging/therapeutic moieties. Another
approach relays on exploration of natural properties or microenvironment in diseased
tissue. It is observed that certain types of malignant cancer (bladder, prostate and etc)
[74] and some other disease conditions show difference in local temperature compared
to normal tissues. Understanding of the differences of local temperature in pathological
sites paved the path to temperature-sensitive delivery systems. Long circulating,
thermo-sensitive nanocarriers can be fabricated and used to exploit microenvironmental temperature differences in diseased sites. For example, in 1978,
Yatvin et al. first time suggested a method to use temperature-sensitive liposomes to
target mild hyperthermia in disease sites. Active or passive targeting methods have to
be first employed to accumulate thermo-sensitive nanocarriers in targeted sites. As the
nanocarriers accumulate in target sites, carried drugs are released in response to the
micro-environmental temperature in more controlled manner.
In general, the thermo-sensitive polymers have the ability to swell and de-swell,
depending on temperature. The two basic types of thermo-sensitive materials are: i)
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positive temperature-sensitive hydrogels that are swollen and hydrated at higher
temperatures and contract on cooling below the upper critical solution temperature
(UCST) and ii) negative temperature-sensitive hydrogels that are swollen at lower
temperatures and contract on heating above the lower critical solution temperature
(LCST). Water solubility of the system decreases as temperature increases. The latest
type of system dominates the literature on drug release applications [75]. Upon the
introduction of UCST/LCST polymers to nanocarrier systems, they gained the ability to
actively respond to the temperature changes in the microenvironment. As they respond
to the environmental temperature these systems remarkably change their features such
as conformation, solubility and hydrophilic/hydrophobic balance to release therapeutic
agents in those sites [76].
Injectable thermo-sensitive hydrogel systems are also considered as potential thermosensitive nano-carries owe to their number of advantages, including simplicity of drug
formulation, protective environment for drugs, prolonged and localized drug delivery,
and ease of application. Chitosan and related derivatives, poly(N-isopropylacrylamide)based

(PNIPAAM)

copolymers,

poly(ethylene

oxide)/poly(propylene

oxide)

(PEO/PPO) copolymers and its derivatives, and poly(ethylene glycol)/ biodegradable
polyester copolymers are widely used by researchers to construct injectable thermosensitive hydrogels [74, 77-80].
DPPC/DSPC are the most common lipids used in making thermo sensitive liposomes.
With the right lipid composition temperature- dependent fusion of liposomes can be
achieved at mild hyperthermia region (39 °C- 42 °C) enhancing increased level of drug
available at the diseased site [75]. Early in vivo work done over a range of tumor
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models, including various carcinomas, sarcomas, and lymph node metastases, and over
a range of drugs, including adriamycin, methotrexate, bleomycin and cisplatin showed
the benefits of temperature-sensitive liposomes when use with mild hyperthermia [8187]. Temperature sensitive nano-systems offer numerous advantages such as
elimination of invasive surgical procedures, the ability to bypass physiological barriers,
and allowing drugs to reach hard-to-access sites in the body, ability to stealth the thermo
sensitive systems against immune system and environmental degradation and ability to
combine this with induced hyperthermia. Owe to extensive studies done in these
systems over past three decades that gives the capability for wide variety of choices to
design nanocarriers of desired architectures.

Limitations of thermo-sensitive

nanocarriers can be overcome by combining them with additional stimuli-responsive
materials.
3.3.4

Targeting hypoxia

Hypoxia (low oxygen concentrations) plays a vital role in many tumors by contributing
to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness,
resistance to cell death, altered metabolism and genomic instability. The hypoxic
regions often lie surrounding areas of necrosis in solid tumors [88-90]. Hypoxiainducible factor (HIF), which is a transcriptional complex, acts as the hypoxia sensor in
a cell. Overexpression of HIF-α, the regulatory subunit of HIF is a measure of increased
vascular density, severity of tumor grade, failure of conventional treatment and
prognosis. Therefore HIF has become an attractive, direct and indirect therapeutic target
in recent years [91-93]. Thambi et al. reported about self-assembled nanoparticles called
hypoxia-responsive nanoparticles, which can selectively release hydrophobic agents
14

under hypoxic conditions [94]. In vivo studies showed selective accumulation of
nanoparticles at the hypoxic regions in tumors compared to normal cells.
Development of hypoxia targeting nanoparticles opens new paths to overcome drug
delivery impediments mentioned earlier. For instance, the brain which demands high
amount of oxygen is vulnerable to hypoxia as a result of irregularity of the blood flow
induced by either cardiac failure, traumatic brain injury, brain cancer or subcortical
vascular disease. Neuronal dysfunction and cell death in major neurodegenerative
diseases also have direct and indirect links to hypoxia. Since HIF involved in virtually
all aspects of the response to hypoxia, HIF based nanocarriers have the potential
advantage of simultaneously regulating the expression of a large number of genes thus
treatment of diseases. However, for HIF related therapies it is vital to discriminate
between various HIF isoforms [95, 96]. Another potential advantage of hypoxia
targeting NPs is the ability to treat inaccessible brain tumors, which cannot be achieved
through conventional surgeries.
3.3.5 Targeting acidity
It’s well known that the cancer cells undergo glycolysis even in the presence of oxygen
which has very significant importance to cancer cells survival and proliferation. As a
result, high glycolytic activity and production of carbonic and lactic acids, which are
intensively pumped out cells to keep intracellular pH near neutral, are common
characteristics of solid tumors. It leads to extracellular acidification of tumor
microenvironment, which promotes cancer invasiveness and aggressiveness [97-100].
This acidic microenvironment is common even for several other diseased tissues, such
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as ischemia, inflammation, arthritis and atherosclerosis. Thus, extracellular acidity
might serve as a general marker for detecting and targeting of diseased tissue.
pH-sensitive nanoparticle systems are the one of the well-studied delivery systems.
These systems contain pH sensitive polymers, lipids or peptides such as pHLIPs (pH
Low Insertion Peptides). Key principle of making pH sensitive fusogenic liposomes is
to identify a lipid which is stable at physiological pH but destabilized upon acidification
following cellular internalization, thereby, promoting the release of their contents into
the cytosol. First generation of such liposomes are designed using the cone shape of
phosphatidylethanolamine (PE) lipids [101]. Cytoplasmic delivery of membraneimpermeable therapeutic agents has been improved by the DOPE-based pH sensitive
liposomes [102-104]. The layer-by-layer (LbL) nanoparticle assembling technique is
developed to prepare pH-sensitive nanoparticles. They contain a pH-sensitive outer
stealth layer which allows targeting and retaining of nanoparticles in acidic tumor
regions [105].
pH sensitive systems can be also achieved by the self-assembled surfactants. They are
mostly known as niosomes and analogues to liposomes. For example, Di Marzio and
colleagues reported that the use of non-ionic surfactants polysorbate 20 and polysorbate
21 together with cholesterol can form highly stable pH sensitive nano-vesicles which
have the potential to deliver both hydrophilic and hydrophobic therapeutic agents to
target sites [106]. pH sensitive systems also show great success for delivering drugs
through oral drug administration due to vast environmental pH differences in
gastrointestinal system [107-109]. The development of highly pH sensitive NPs to target
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acidity helps not only for treatments but also for diagnosis of wide array of carcinomas
and many other pathological diseases.
4. pHLIP-technology
The pHLIP technology, which was introduced several years ago, has been showing
success in targeted drug delivery for cancer and other pathogenic conditions. pHLIP,
being a membrane peptide, has affinity to cellular membranes and it targets extracellular
acidity. In contrast to other pH-sensitive systems, it “senses” acidity at the surface of
cancer cells, where pH is the lowest due to the reversed pH gradient compared to cells
in healthy tissue [110].
4.1. Molecular mechanism of pHLIP action
The original pHLIP composed of 36 amino acids is an isolated C-helix of
bacteriorhodopsin. The water-soluble pHLIP peptide has been observed to behave
differently at different pHs when it is in the vicinity of the lipid bilayer. The pHLIP
binds to lipid bilayer surfaces as an unstructured monomer above pH 7, and it
spontaneously inserts as an α-helix across lipid bilayers at low pH, with a pKapp of 6
[111]. The insertion of pHLIP into membrane, is reversible and unidirectional, in most
cases the C-terminus is translocated across the membrane whereas the N-terminus stays
outside of the membrane [112, 113]. The opposite occurs for reverse sequence [114].
The insertion mechanism is based on the protonation of Asp/Glu residues located in the
membrane inserting parts of the pHLIP [111, 115-117]. The thermodynamics and
kinetics of pHLIPs membrane-associated folding and insertion has been extensively
investigated. Peptide’s three major forms (in solution, attached to, and inserted across
lipid bilayers ) are monomeric at peptide concentration less than ~ 7 µM [112]. The
17

process of insertion and folding (helix formation) is fast and varies from milliseconds
to minute depending on peptide sequence (Andreev et al., 2010; Karabadzhak et al.,
2012). The energy of peptide’s association with bilayer is about 6-7 kcal/mol [113]. As
pHLIP inserts into the membrane and folds it releases additional energy (about 2
kcal/mol) [113], which could be utilized to tether cargo molecules to the surface of
cancer cells (Fig 1a), or move cell impermeable cargo molecules across the membrane
into a cell (Fig. 1b). It has been shown tumor targeting of fluorescent, PET and SPECT
probes attached to the N-terminus of pHLIP [118-123]. As biological membrane
remains the main barrier for cytoplasmic drug delivery it was demonstrated that the
energy of membrane-associated folding of pHLIP can be used to successfully deliver
into cells polar and membrane-impermeable molecules including cyclic peptides,
toxins, peptide nucleic acids (PNAs) linked to pHLIP’s C-terminus via cleavable links
[124-128]. Over a decade the original pHLIP peptide has given birth to more than 20
pHLIP variants and available to use as probing and delivery agent [114]. The ability of
pHLIP to probe extracellular acidic environment, which is associated with tumors and
many other pathological conditions has opened new avenues for future drug delivery.

4.2.

pHLIP based nanomedicine

Roughly a half a century ago, a British biophysicist and a medical scientist, Alec
Bangham made a remarkable observation that phospholipids in aqueous systems can
form closed bilayered structures and named them Bangasomes. Today we call them
liposomes. After Bangham and his collaborators established the existence of liposomes,
the liposomes have moved a long journey from being just another exotic entity of
biophysical and colloidal science research and became a pharmaceutical carrier of
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choice for various real-world applications, as we outlines in previous sections. As a
result of that, now liposomal drugs has approved for clinical applications or they are
undergoing clinical evaluation [129].
When pHLIP is introduced to the conventional liposomes as a coating moiety (Fig. 1c),
it allows to enhance the therapeutic value of the liposomes. It was shown that the
presence of pHLIP on the surface of PEGylated-liposomes enhanced membrane fusion
and lipid exchange in a pH dependent fashion, leading to increase of cellular uptake and
payload release (Fig. 1d), and inhibition of cell proliferation by liposomes containing
ceramide [130]. For liposomal drug production and storage the controlling of their size
becomes a major issue. When liposomes are in storage they could fuse with each other
and give a poly-disperse liposomal mixture and diminish the desirable properties as
nano-carriers.

The same study [131] reveals that liposomes containing just 5% of

pHLIP lipid composition minimize inter-liposomal fusion and make them stable for
several days if stored at neutral pH, since pHLIP brings overall negative charge to the
surface of liposomes at neutral and high pHs. At the same time, drop of a pH leads to
the protonation of Asp/Glu residues, reduces overall negative charge at the surface of
liposomes and enhances interaction of pHLIP-coated liposomes with cellular
membranes. It was studied the interaction between pHLIP-coated liposomes and cells
as a function of incubation time of 15 min vs. 60 min and it was shown existence of
different pathways of liposome-cell interaction. Predominantly direct liposomal fusion
with plasma membrane occurs during short incubation period; while during long
incubation period, both fusion and cellular internalization through endocytosis (most
probably, macro pinocytosis) could happen. Since pegylation helps to prevent

19

opsonization, it promotes longer circulation of liposomes in blood, and enhances
probability for liposomes to interact with cell membrane in a pH dependent manner.
Thus, the pH-sensitive, "fusogenic" pHLIP-coated liposomes could be used to
selectively deliver various diagnostic and therapeutic agents to acidic diseased cells.
Emmetiere et al. [132] (Emmetiere et al., 2013) introduced dual-delivery approach using
pHLIP to tether liposomes to cancer cells in tumor [132]. First, pHLIP was conjugated
to the tetrazine (Tz), which is one of the bioorthogonally reactive small molecules to
form pHLIP-Tz conjugate. pHLIP-Tz was injected into mice to selectively label the
surface of cancer cells. Then, bioorthogonally reactive trans-cyclooctenes coated
liposomes containing
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F PET isotope were given as a second injection. The long

circulating radiolabeled liposomes were accumulated in tumor sites mainly via EPR
effect, followed the click reaction between tetrazine-pHLIP and trans-cyclooctenes in
liposome coat resulting in covalent conjugation and tethering of liposomes to cancer
cells. This in vivo click reaction allows achieving high signal/noise ratio, higher
accumulation of radiolabeled liposomes in tumor site, low nonspeciﬁc binding and
reduced toxicity to kidneys and bone marrow.
According to the World Health Organization statistics the ischemic heart diseases are
the top leading cause of death, affecting millions of men and women worldwide. Several
techniques for passive and active imaging and as well as drug delivery to the diseased
cardiac tissue have been developed during past few years [133, 134], which including
different types of nanoparticles for drug delivery such as liposomes, drug–polymer
conjugates, polymeric micelles, dendrimers, nanoshells, and nucleic acid-based carriers
[129, 135, 136]. A study was done to evaluate ability of pHLIP-coated liposomes to
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target ischemic myocardium using two murine ischemia models: regional ischemia
induced by coronary artery occlusion and global low-flow ischemia in isolated hearts
[137]. In both models, two candidates from the pHLIP family (WT and Var7) were
chosen along with pH insensitive kVar7 (K-pHLIP), which has Lys instead of key
Asp/Glu residues and cannot insert into membrane at any pH [114]. It was shown that
pHLIP-coated liposomes bind to ischemic regions but not to normal myocardium while
kVar7 and liposomes coated just with PEG (no pHLIP) do not show any targeting
[137]. The study ensures that pHLIP-coated liposomes have the ability to target
ischemic regions with therapeutic agents as well as to mark disease regions to assist
pHLIP-fluorescent-aided cardiac surgeries.
Another novel approach of pHLIP-coated-liposomes is the delivery of nano-pores to
induce apoptosis in cancer cells [138]. Proper ion balance between intracellular and
extracellular media is crucial for normal cell functioning. Any alterations in the
conductance of membranes for ions will lead to cell death. To change cellular ion
ballance the pore-forming gramicidin A (10 mol%) was delivered to cellular membrane
using pHLIP-coated DOPC liposomes. Liposomes were stable for more than a month
in 4 °C. Hydrophobic gramicidin A monomers were introduced into pHLIP-coatedliposomes, where it makes beta-helices and forms transmembrane porse with diameter
of 4-5 Å that can transfer monovalent cations through the membrane at rate of 107
cations per second [139]. As we outlined above, when pHLIP-coated liposomes target
cancer cells, they either fuse with the plasma membrane or are up-taken by endocytosis
and then fuse with lysosomal membranes. It leads to delivery of gramicidin A pores
(nano-pores) to cellular membranes of cancer cells. These nano-pores acidify the
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intracellular space and eliminate the vital Na+/K+ ion balance. This method not only
opens pathways to treat acidic solid tumors, but also give opportunity to deliver various
membrane peptides and proteins to the cells, widening the applications in biotechnology
and nano-medicine.
Nano-gold particles have also caught attention in pHLIP-nanotechnology. Beneficial
properties of gold in medicine has been considered for centuries [140]. And gold has
been used in modern science as a contrast agent in electron microscopy. There are wellestablished methods to obtain uniform stable gold nano-structures in the range of few
nanometers up to couple hundred of nanometers [141]. Tuning size and shape of nanogold structures allows to obtain unique physical properties, which can be very useful for
multiple applications across both therapeutics and diagnostics [142]. Functionalized
nano-gold particles are valuable for wide variety of nanomedicinal uses and now they
are undergoing through evaluations of toxicity [141], stability [143], pharmacokinetics
[144], cellular trafficking [145-148], efficacy for gene regulation [149] and drug
delivery [147], and use in photo-thermal therapies [150, 151].
Lan et al. showed that nano-gold particles which are 1.4 nm size in diameter conjugated
to N-terminus of pHLIP can successfully target cancer cells at low pH [131]. In vivo
studies done using mice-tumor models demonstrated high tumor uptake in both
intravenous and intra-tumoral administration compared to non-functionalized nanogold particles. The beauty of pHLIP-nano gold technology is in its capability of
providing the specific targeting, enhancing local concentration in tumor mass in
homogeneous way while remaining in cells for an extended period (several days), by
allowing applications of radiation therapy and imaging.
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Davies and colleagues employed pHLIP to deliver luminescent europium coated
nanoparticles into platelets [152]. The 13 nm gold nanoparticles were co-coated with a
europium luminescent, EuL and the pHLIP to give pHLIP.EuL.Au. Human platelets are
vulnerable to transfection or microinjection. But with this method authors could deliver
nanoparticles which have roughly 640 lanthanide probes per particle. The result shows
that the internalization of nanoparticles into the platelets happened only at low pH and
not at normal pH. The significance of this research is that pHLIP can translocate
multimodal nanoparticles in a pH dependent manner.
Non-viral vectors are also a hot topic in gene therapy due to their advantages over viral
vectors such as simplicity of use, ease of large-scale production and lack of specific
immune response [153]. Recently it was reported a novel use of pHLIP to deliver pDNA
to tumor cells [154]. DGL-PEG-pHLIP were made by conjugating the surface of
dendrigraft poly-L-lysines (DGLs, generation 3 with 123 amino groups per molecule)
to the N-terminus of pHLIP followed by electrostatic interactions between negatively
charged pDNA and positively charged DGL head group of DGL-PEG-pHLIP to create
DGL-PEG-pHLIP/pDNA nanoparticles. Results of in vitro studies showed that higher
cellular uptake of nanoparticles occurs at low pH (pH 6.0) compared to normal pH (pH
7.4) and nanoparticles enter cells mainly by adsorptive mediated endocytosis. The in
vivo studies also followed the same pattern by showing high tumor uptake of DGLPEG-pHLIP/pDNA nanoparticles. It was clear that pHLIP enhanced the pH-controlled
localization of the nanoparticles in tumors.
Zhao and colleagues (2013) show that pHLIP peptide not only targets acidic tumor
micro environment but also it can release nanoparticles in a controlled manner to the
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intracellular space. They chose mesoporous silica nanoparticles (MSN), in particular
MCN-41, to load with doxorubicin. MSN has the attributes of high homogeneous
porosity, inertness, biocompatibility, high payload capacity and easy surface
functionalization capability. The MSN particles were attached to the C-terminus of
pHLIP by disulfide bond. At low pH (< 6.5), doxorubicin-loaded pHLIPss-MSN rapidly
inserted into the cell membrane and translocated MSN into cytoplasm. The disulfide
bond was cleaved in cytoplasm to release doxorubicin.

5. Conclusion
There are several challenges for targeted nano drug delivery systems to overcome. Still
most of these drug systems undergo in vitro and in vivo testing using animal models.
Therefore their relevancy to the real patients has to be evaluated extensively. Each nano
drug platform is distinctive and need to be assessed experimentally as new system,
which is strenuous. Nanoparticles stability, size uniformity, controlled drug release rate,
sterile preparations in large scale and manufacturing cost have to be addressed in order
to make them available to the market. But with recent scientific advances, next ten
years it is expected to see large number of targeted drug delivery systems based on
nanoparticles in the market. pHLIP nanotechnology has been showing its potential
capability to address most of the challenges mentioned above. pHLIP technology used
alone or combined with other approaches might lead to new formulations translatable
to clinics.
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Tables
pHLIP
nanotechnology
PEGylated-liposomes
containing ceramide
pHLIP-Tz conjugates
and trans-cyclooctenes
coated liposomes
containing 18F PET
isotopes
WT and Var7 coated
liposomes

pHLIP liposomal
nano-pores

pHLIP nano-gold
particles
Eu coated pHLIP
nanoparticles

pDNA nanoparticles
dox MSNs

How it works

Administration

Authors

Increase ceramide levels in
cancer tissues promote cell
death and tumor inhibition
Tetrazine(Tz) labeled cancer
cells are targeted by transcyclooctenes coated
liposomes to radio label the
tumor site
pHLIP coated liposomes
binds to ischemic regions and
assist pHLIP- fluorescent aided cardiac surgeries
Hydrophobic gA is delivered
to cancer cells to form
channels in cell membrane to
destroy ion balance and
induce apoptosis
Homogeneous accumulation
of gold in tumor sites allow
radiation therapy and imaging
At low pH, more lanthanide
probes can be internalized to
human platelets breaking the
targeting barrier
High uptake of DGL-PEGpHLIP/pDNA in tumors
Dox are loaded to porous
silica nanoparticles and
deliver to cancer cells using
pHLIP

In-vitro , In-vivo

[155]

In-vivo

[132]

In-vivo

[137]

In-vitro

[138]

In-vivo

[131]

In-vitro

[152]

In-vivo, In-vitro

[156]

In-vitro

[157]

Table 1. Current pHLIP applications in nanotechnology
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Figures

Figure1. Different applications of pHLIP for targeting of acidic tissues. Tethering
of cargo molecules to the surface of cells (a). Cytoplasmic delivery of cargo molecules
and it’s release by break of cleavable link (shown in blue) (b). Assembly of
multifunctional pHLIP-coated liposomes containing polar (green) and hydrophobic
(yellow) payloads (c). Schematic presentation of interactions of lipid bilayer of the
pHLIP-coated multifunctional liposomes with plasma membrane of a cell (presentation
of liposome in the endosome is schematic and not in a scale) (d).
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Abstract
Proper balance of ions in intracellular and extracellular space is the key for normal cell
functioning. Changes in the conductance of membranes for ions will lead to cell death.
One of the main differences between normal and cancerous cells is the low extracellular
pHe and the reverse pH gradient: intracellular pHi is higher than extracellular pHe. We
report here pH-selective transfer of nano-pores to cancer cells for the dis-regulation of
balance of monovalent cations to induce cell death at mildly acidic pHe as it is in most
solid tumors. Our approach is based on the pH-sensitive fusion of cellular membrane
with the liposomes containing gramicidin A forming cation-conductive 𝛽-helix in the
membrane. Fusion is promoted only at low extracellular pH by the pH (Low) Insertion
Peptide (pHLIP®) attached to the liposomes. Gramicidin channels inserted into the
cancer cells open flux of protons into the cytoplasm and disrupt balance of other
monovalent cations, which induces cell apoptosis.
Introduction
The control of intracellular pH and balance of ions in a cell are essential for a
number of important physio- logical processes, such as protein, DNA and RNA
synthesis and control of the cell cycle[1]. In cancerous tissue the balance of
protons is disturbed, which leads to acidification of the extracellular milieu and
reversing of the transmembrane pH gradient compared with normal tissue: the
intracellular pH (pHi) in tumors is higher than the extracellular pH (pHe)[2, 3].
The equilibration of the extracellular and intracellular pHs as well as disruption
of balance of other ions will lead to cell death. We propose to transfer in a pH-
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dependent manner nano-pores to the plasma membrane of cancer cells to disrupt
intracellular and extracellular ion balance and induce cytosol acidification.
Nano-pores will be formed by linear hydrophobic peptide, gramicidin A (gA),
consisting of alternating L- and D-amino acids, which forms cation-conductive 𝛽helix in the membrane[4-6]. The diameter of gA 𝛽- helix channel is about 4–5 Å ,
which can conduct about 107 cations per second[5]. The high conductance is
observed
for the protons, sodium and potassium ions. The gA channels formed in the
liposomes will be delivered to the membrane of cancer cells by fusion. The
fusion between the lipid bilayer of liposome and cancer cells will be promoted
by the pH (Low) Insertion Peptide (pHLIP®). The pHLIP inserts into the lipid
bilayer and forms transmembrane helix at pH < 7 [7, 8], and therefore is able to
bring in close contact liposome and cellular membranes only at low pH. We have
demonstrated that the pHLIP-based optical, PET and SPECT imaging agents can
target acidic diseased tissue[9-13], and we proved that pHLIP technology can
substantially improve delivery of nanopar ticles and liposomes to the acidic
diseased tissue[14, 15]. The presence of pHLIP on the surface of PEGylatedliposomes enhanced membrane fusion and lipid exchange in a pH dependent
fashion, leading to the increase of cellular uptake and payload release[16]. In the
present study we demonstrate that the pHLIP-coated liposomes could be used to
transfer nano-pores (peptide channels) into the membrane of cancer cells,
disrupt transmembrane pH gradient and balance of sodium ions, which leads to
the apoptosis of cancer cells.
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Materials and Methods
Materials
Gramicidin A (gA) (from Bacillus brevis) ≥ 90%(HPLC), N-(fluorescein-5thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine,
triethylammonium salt (FITC-DHPE) were purchased from Sigma-Aldrich. 1,2dioleoyl-sn-glycero-3-phosphocholine

(DOPC),1,2-dioleoyl-sn-glycero-3-

phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide]

(sodium

salt)

(DSPE-maleimide), were obtained from Avanti Polar Lipids. The pHLIP peptide
(ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT) was prepared by
solid- phase peptide synthesis at the W.M. Keck Foundation Biotechnology
Resource Laboratory at Yale University. 3,3’-dimethyl-a-naphthoxacarbocyanine
iodide (JC-9),

nigericin,

SNARF

(seminaphthorhodafluors)-5F

5-(and-6)-

carboxylic acid, acetoxymethyl ester, acetate and CoroNa TM Green, AM were
purchased from Invitrogen. Water was purified using a Millipore Milli-Q system.
Synthesis of DSPE-pHLIP
DSPE-pHLIP was synthesized by conjugation of DSPE- maleimide with single cysteine
residue at the N-terminus of pHLIP. In a typical coupling reaction, 1200 nmol of peptide
was mixed with 1000 nmol of DSPE- maleimide in 400 µL of degassed methanol and
incubated overnight stirring at room temperature under argon.
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Liposome preparation
Liposomes were prepared by extrusion: a chloroform solution of the 80–98 mol% of
DOPC lipids mixed with 5% pHLIP conjugated lipids (pHLIP-DSPE), 2–5%
fluorescent labeled lipids (FITC-DHPE) and 0–10% gA were evaporated using rotary
evaporator producing an even thin film, followed by the additional overnight
evaporation under the high vacuum to remove traces of organic solvents. This lipid
layer was re-suspended in 1 mL 10 mM phosphate, 150 mM NaCl buffer and went
through 10 freeze-thaw-vortex cycles. The resulting liposome solution was extruded
31 times through 50 or 100 nm filters, which were used for biophysical
measurements and experiments on cultured cells, respectively.
Liposomes were sterilized by filtering through 0.2 µm filter before addition to
cells. Solution of liposomes was kept at 4℃ overnight before use to ensure gA
channels formation. The concentration of lipids was calculated by measuring
absorbance of FITC at 496 nm (ε= 89,000 M
-1

nm (ε =21,000 M

-1

cm

-1

cm-1) or gA and pHLIP at 280
-1

for gA and ε= 13,940 M

-1

cm

for pHLIP) of the

liposomes dissolved in methanol.
DLS and Zeta potential measurements
The size of liposomes was measured by the dynamic light scattering (DLS) using a
Malvern Zetasizer Nano ZS instrument with Malvern disposable cuvettes (Malvern
USA). Samples were typically 100 nmol liposomes in 1 mL of 10 mM phosphate,
150 mM NaCl, pH 7.4 buffer. The zeta potential was measured on the same
instrument using folded capillary cells from Malvern.
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Cryo-electron microscopy
About 5 µL droplet of liposome solution was spread on a Lacey Formar/Carbon
electron microscopy grid and preserved in a frozen-hydrated state by a rapid
freezing in liquid ethane. The vitrification process was performed via FEI Vitrobot
system with the setting of a single blot of 3 sec, an offset of 1, and drain and wait
time of 1 sec. Samples were imaged using JEOL 2100 TEM with an accelerating
voltage of 200 kV at magnifications of 20,000× and 40,000×.
Steady-state fluorescence and circular dichroism measurements
Tryptophan fluorescence and circular dichroism (CD) measurements were carried
out on a PC1 ISS spectrofluorometer (ISS, Inc.) and a MOS-450 spectrometer (BioLogic Inc.), respectively. All measurements were performed at 25℃. DOPC
liposomes containing 0, 2% or 10% of gA were used in the study in phosphate buffer,
pH 7.4. Fluorescence spectra of gA at excitation of 280 nm was recorded from 310
nm to 400 nm with the spectral widths of excitation and emission slits set at 4 and
2 nm, respectively. CD spectra were recorded from 200 to 260 nm with 0.5 nm
increment using a cuvette with an optical path length of 0.5 cm.
Kinetics of FITC quenching
DOPC liposomes containing 2% and 10% gA, 2% FITC-DHPE and liposomes
containing no gA were used in the kinetics studies. All solutions were degassed
several minutes under a vacuum to minimize air bubbles before loading into
syringes of the stopped-flow apparatus (Bio-Logic, Inc.). Liposomes of 1.5 mM
lipid concentration in 10 mM phosphate buffer pH 8 (or pH 3) with 150 mM NaCl
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were rapidly mixed (within 5 ms – dead time of the set up we used) with an equal
volume of HCl (or NaOH) to have final pH of 3 (or pH 8). Changes of the
fluorescence intensity of FITC at 519 nm excited at 496 nm were monitored in a
real time. Baseline was measured by mixing the liposomes with equal volume of the
buffer.
Cell lines
A549 (lung carcinoma), HeLa (human cervix adenocarcinoma) and M4A4 (human
breast ductal carcinoma) cell lines were obtained from American Tissue Culture
Collection (ATCC). Cells were authenticated, stored according to the supplier’s
instructions, and used within 3 months after frozen aliquot resuscitations. Cells were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 1% penicillin/streptomysin, 1 µg/mL of ciprofloxacin in a
humidified atmosphere of 5% CO2 and 95% air at 37 ℃. By serial passages some cells
were adapted for the growth in low pH media (pH 6.2). The pH media was prepared
by mixing 13.5 g of dry DMEM powder with 0.1 g of sodium bicarbonate in 1 L of
deionized

water

supplemented

with

10%

fetal

bovine

serum,

1%

penicillin/streptomysin, 1 µg/mL of ciprofloxacin.
Proliferation assay
About 3,000–4,000 of A549 cells were seeded in 96 well-plates at pH 7.4 and 6.2.
After 24 hrs, cells were treated for 3 hrs with various concentrations of pHLIPcoated DOPC liposomes in DMEM at pH 7.4 and 6.0 followed by addition of an
equal volume of DMEM with 20% FBS. In other experiments, cells were treated with
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liposomes for 18 hrs followed by the removal of the constructs and replacement of
the media with DMEM containing 10% FBS. For the control experiments cells were
treated at both normal and low pHs with the DOPC liposomes containing no gA or
no pHLIP. Cells were grown until non-treated cells in control reached 80–90%
confluence. Cell viability was assessed by the colorimetric reagent (CellTiter 96
AQueous One Solution Assay, Promega) of the MTS (3-(4,5-dimethylthiazol-2-yl)5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, which was
added for 1 hour to cells followed by measuring absorbance at 490 nm. All samples
were prepared in triplicate. Each experiment was repeated several times.
ECIS assay
Kinetics of inhibition of proliferation of A549 cells treated with the pHLIPcoated DOPC liposomes containing 10% gA and 5% pHLIP at pH 6.0 were
monitored by the changes of capacitance measured at AC frequencies on a ECIS®
8Z (electric cell-substrate impedance sensing) instrument (Applied Biophysics,
Inc.). Cells (25,000 cells per well) were loaded in 8W10E+ 8-well plate (Applied
Biophysics, Inc.) and incubated overnight. Next day, the cells were treated with
different concentrations of liposomes in serum free pH 6.0 media for 3 hrs
followed by addition of an equal volume of DMEM containing 20% FBS at pH
6.2. Each well had two sets of 20 circular 250 µm diameter active gold electrodes.
The changes of capacitance were monitored within 5 days after seeding of cells.
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Intracellular pH measurements
First, pH calibration curve was established: about 40,000 A549 cells were seeded in
collagen coated glass bottom dishes (MatTek, Corp.) at pH 6.2. Next day cells were
incubated with 20 mM of SNARF-5F in L-15 phenol red free media at pH 6.2 for 1 hr
followed by washing three times with 50 mM phosphate/ citric acid solution at pH
5.5, 6.0, 6.6, 7.2 or 7.5. Next, 25 µl of 0.4 µg/ml nigericin was added to cells and
incubated for 15 min to equilibrate the intracellular pH with the pH of buffer.
Fluorescent spectra of SNARF-5F before and after addition of nigericin to the cells
were recorded in the range of 520–800 nm on a fluorescent inverted microscope
IX71 (Olympus America, Inc.) with an attached Shamrock 303 (AndorTechnology,
Inc.) spectrograph equipped with a Newton EMCCD (electron multiplied charged
couple device) camera (Andor Technology, Inc.) using 480 ±10 nm excitation an
interference filter and a long pass emission filter with 520 cutoff wavelength. Ratio
of SNARF-5F fluorescent signal at 595 nm/640 nm were calculated for each pH and
plotted against the respective pH, and fitted with a linear function using Origin9
software (Origin Lab, Corp.) to obtain calibration curve. In separate experiment
A549 cells were treated at pH 7.4 and 6.0 with 250 µM of the DOPC pHLIP-coated
liposomes containing 0 or 10% gA and 5% pHLIP for 3 hrs followed by the addition
of an equal volume of 20% FBS in DMEM and incubated overnight. At various days
after the treatment cells were incubated with 60 µM SNARF-5F in 200 ml of L-15
pH 6.2 for 1 hr, followed by washing with L-15 of pH 6.2 and recording SNARF-5F
emission spectra. Next, nigericin was added to the cells to equilibrate pH and
emission spectra of SNARF-5F were recorded once again. The SNARF-5F
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emissions signal ratio of 595/640 nm was calculated and the corresponding
intracellular pH was established using pH calibration curve.
+

Intracellular Na measurements
About 30,000 A549 cells of pH 7.4 and 50,000 A549 cells adapted to pH 6.2 were
seeded in the collagen coated glass bottom dishes. Next day, cells were treated with
1 mL of 250 µM lipid concentration of the DOPC liposomes with 10% gramicidin
and 5% pHLIP (control – equal volume of PBS 7.4) in pH 6.2 and pH 7.4 DMEM
without FBS and incubated for three hours. After 3 hours 1 ml of 20% FBS in
DMEM medium at pH 6.2 and pH 7.4, respectively, were added and incubated until
the experiments were performed. Next day, the treatment solution from the control
and treated dishes was removed and 100 µl of 100 µM CoroNaTM Green AM
solution in L-15 at pH 7.4 was added and incubated for 45 min. After 45 mins, cells
were washed three times using PBS and imaged in L-15 at pH 6.2 or pH 7.4 using
green channel of the fluorescent microscope. The same procedure was repeated with
the treated and control cells on 3rd day after the treatment.
Quantification of the fluorescent signals from the cells was performed using an
ImageProPlus software. Statistical analysis of the data was performed using the
‘‘Statistica 5.0’’ package. The p-level was computed based on the two-tailed test.
Mitochondria depolarization assay
About 30,000 A549 cells were seeded in the collagen coated glass bottom dishes.
Next day, cells were treated at pH 7.4 and 6.2 with 1 mL of 250 µM lipid
concentration the DOPC pHLIP-coated liposomes containing 10% gA and 5%
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pHLIP for 3 hrs followed by addition of an equal volume of DMEM containing 20%
FBS at corresponding pH. At various days after the treatment cells were incubated
with 10 µg/mL JC-9 solution in L-15 at pH 7.4 or 6.2 for 15 min followed washing
and imaging. Imaging was performed on a fluorescent inverted microscope IX71
(Olympus America, Inc.) using color Q-Color3 CCD camera (Olympus America,
Inc.). The following excitation and emission filters were used: for green channel 490
± 10 and 520 ± 10 nm; and for yellow channel 540 ± 10 and 580 ± 10 nm.
Quantification of fluorescent signals from the cells was performed using an
ImageProPlus software. Statistical analysis of the data was performed using the
‘‘Statistica 5.0’’ package. The p-level was computed based on the two-tailed test.
Results
Preparation of liposomes and biophysical studies
We introduced pH-sensitive fusogenic liposomes containing 80 mol% of DOPC
lipids, 5% of DSPE-maleimide lipids conjugated with Cys residue at the Nterminus

of

pHLIP

peptide

(ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT), 5% of fluorescein
(FITC) labeled lipids and 10% of gramicidin (gA: formyl-(L)W-(D)G-(L)A-(D)L(L)A-(D)V-(L)V-(D)V-(L)W-(D)L-(L)W-(D)L-(L)W-(D)L-(L)Wethanolamine) (Figure 1a). The DOPC pHLIP-coated liposomes containing gA
formed single lamellar structures of the average size of about 120 nm in
diameter (the polidespersity 0.07 ± 0.01 and zeta potential -230.7 ± 1.8 mV),
which were stable within a month if kept at 4℃ (Figure 1a, b SI). The liposome
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surface was stabilized by the negatively charged pHLIP peptides. Our previous
data indicate that one pHLIP molecule in its extended configuration can occupy
about 120 lipids at pH 8[17]. Thus, 5% of pHLIP in liposome (about 3% on the
outer surface) should fully cover liposome surface. Control liposomes
containing gA, but no pHLIP and containing pHLIP, but no gA were also tested.
Gramicidin A is a linear peptide spanning just half bilayer and capable of
adopting different configurations. Single stranded helical form, when two
monomers of gA located within inner and outer leaflets of bilayer form head-tohead dimer, corresponds to the channel (pore) configuration of 4–5 A˚ in

the

diameter (Figure 1b). Gramicidin in the channel configuration exhibits
characteristic circular dichroism (CD) signal and short wavelength shift of
the tryptophan fluorescence spectrum[18], monitored by us and shown on
Figure 2a and Figure 2b, respectively. To demonstrate conductance of
protons by the gA channel we performed kinetics measurements on
liposomes containing 2% DHPE lipids head groups of which were labeled
with FITC. The FITC carries two negative charges at pH 9. As the pH is
lowered the carboxyl groups of FITC are protonated and FITC is transferred to
the non-fluorescent non-charged form. Thus, decrease of pH from 9 to 3 is
associated with the decreased of fluorescence. The pH 8 → 3 transition was
induced by fast mixing (5 ms dead time) of the DOPC-FITC liposomes and HCl
in the stopped-flow apparatus. The sudden decrease of about 75% of fluorescent
signal was associated with the quenching of emission of FITC on the outer leaflet
of bilayer. The quenching was completed within a dead time (5 ms) followed by
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the slow kinetics reflected penetration of the protons across a bilayer. It led to
the quenching of fluorescence of FITC located at the inner leaflet of bilayer (red
line on Figure 2c). The data are in an accordance with the previously published
results[19, 20]. At the same time, when 2% or 10% of gA was incorporated into
liposomes the decrease of FITC fluorescence was completed within less than 5
ms due to the conductance of protons by the gA channel (blue line on Figure
2c). We also followed pH equilibration after the addition of base to induce pH 3
→ 8 transition, which leads to the increase of FITC fluorescence. For the
liposomes containing gA the changes of fluorescence were completed within
less than 5 ms. At the same time, the slow kinetics was observed for the liposomes
containing no gA (Figure 2d).
Inhibition of cell proliferation
Biophysical studies indicated that gA is adopting conductive channel form in the
liposomes. The main question we proposed to answer if the pHLIP-coated
liposomes will be able to transfer gA channel to the cellular membranes of
cancer cells, destroy ion balance and induce cell death. All experiments were
carried out on the cancer cells growing in standard DMEM media pH7.4 and on the
cells adapted for low pH growth of 6.2 in DMEM. First, we tested ability of the
pHLIP-coated liposomes containing 5 and 10% gA to inhibit proliferation of A549
lung carcinoma cells adapted for low pH growth (Figure 2a SI). Cells were treated
at pH 6.2 with the constructs for four days. The liposomes containing 10% gA were
more effective in inhibition of cell proliferation, since increase of the gA
concentration in membrane significantly raise the probability of assembling of
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conductive channel, when both monomers come toge- ther and form head-to-head
b-helix. The liposome composition containing 10% gA was selected for further
experiments.

A549

(human

lung

carcinoma),

HeLa

(human

cervix

adenocarcinoma) and M4A4 (human breast ductal carcinoma) cell lines were
treated with the pHLIP-coated liposomes containing 10% gA and 5% pHLIP for 18
hrs at pH 7.4 or pH 6.2 in DMEM followed by the replacement of media with
DMEM containing 10% FBS. MTS assay was performed on 4-th day after the
treatment to establish number of viable cells (Figure 3a–c). More than 80% of cells
were dead in the result of treatment with the liposomes of 10 mM of total lipid
concentration at pH 6.2. At the same time, the treatment of cells with the same
construct at pH 7.4 did not affect cell proliferation, except of M4A4 cells at the
highest concentration of the construct. We also treated A549 cells for 1 day in
DMEM of pH6.2 and then transferred cells into the pH7.4 DMEM with 10% FBS
(Figure 3c). When cells treated at low pH were transferred to normal pH the
cytotoxic effect was significantly less. In a control experiment, the same cell lines
were treated at the same conditions with the pHLIP- coated liposomes with no gA
at concentrations up to 100 µM at both pHs and no any effect on cell proliferation
was observed (Figure 2c–d SI).
No inhibition of A549 cells proliferation was also observed, when cells were
treated for 4 days with the liposomes containing 10% gA and no pHLIP at
concentration of up to 500 µM at both pHs (Figure 2b SI). Thus to induce
inhibition of cell proliferation the liposomes need to be i) coated with pHLIP,
ii) contain gramicidin channels and iii) incubated with cells at low pH. The
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kinetics of inhibition of proliferation of A549 cells treated with the pHLIPcoated liposomes containing 10% gA at pH 6.2 was monitored by the changes
of capacitance measured at AC frequencies using the electric cell-substrate
impedance sensing (ECIS) technique (Figure 3d). The capacitance varies in a
linear fashion with the fractional cell coverage of the bottom of special chamber
coated with the thin film gold electrodes connect to the ECIS electronics[21].
When cells were shrinking and dying after the treatment with the construct the
capacitance was increasing. The cell death happens couple days after the
treatment.
Acidification of intracellular space
We assumed that the pHLIP- coated liposomes fuse with the cellular membrane
and deliver gA channels to the plasma membrane. The efficient conductance of
protons of gA channel from the extracellular space to cytoplasm leads to the
acidification of intracellular space. The pH-sensitive fluorescent dye SNARF
was used to measure pH in a cell[22]. SNARF in the ester form can freely diffuse
across the membrane into cytoplasm, where in the result of esterification it is
transferred to the cell-impermeable fluorescent carboxyl acid. Fluorescence of
carboxy SNARF at 595 nm increases with pH changes from 8 to 5. Fluorescent
spectra from the cells (Figure 4a) were recorded using an Andor spectrometer
coupled with a fluorescent microscope. Nigericin, K+/H+ ionophore, was used
to disrupt balance of the protons and equilibrate pH between the extracellular and
intracellular spaces, which was needed for the calibration of the fluorescent signal
of SNARF in cells[23]. Ratio of SNARF fluorescent signals at 595 nm to 640 nm
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were calculated for each pH and plotted against the respective pH, which
allowed constructing the calibration curve (Figure 4b). Then, fluorescent signal
of SNARF was measured in A549 cells treated with the pHLIP-coated
liposomes containing 10% gA and non-treated cells. First day after the
treatment, the pH inside the non-treated (control) and treated cells was 7.08 and
7.02, respectively (Figure 4b, blue and magenta circles). However, on the second
day after the cells treatment the intracellular pH was dropped to 6.53 (Figure 4b,
red circle), while the intracellular pH in the control group was around 7.23 (Figure
4b, green circle). After each measurement of intracellular pH, the nigericin was
added to the cells, and the measured pH was found to be around 6.2–6.3 in each
case as expected, as a pH of L-15 media used in the experiment.
Disruption of cellular balance of Na+ ions
It is known that gramicidin pore conducts well not only protons, but all
monovalent cations including sodium and potassium ions. We used sodium ion
indicator, CoroNa Green dye, that exhibits an increase in green fluorescence
upon binding Na+

in presence of

physiological concentrations of other

monovalent ions[24, 25]. A549 cells non-treated and treated with the pHLIPcoated liposomes containing 10% gA at both 7.4 and 6.2 pHs were loaded at
different time points with the cell-permeable CoroNa Green AM, washed and
imaged. We observed enhancement of the green fluorescence of cells treated
with the liposomes at low pH on day 1 and even more significant increase of
fluorescence on day3 (Figures 5). It indicates the equilibration of concentration
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of sodium ions in the extracellular and intracellular spaces in the result of
transfer of sodium ions into the cytoplasm via the gramicidin channel.
Mitochondria depolarization assay
Disturbance of the balance of monovalent ions and acidification of the
intracellular space induces

apoptosis,

which

was

monitored

by the

depolarization of mitochondria. Membrane-permeable dye, JC-9, exhibits
potential- dependent accumulation in the mitochondria monitored by the
fluorescence emission shift from green (~530 nm) to orange (~590
nm)[26]. Consequently, the mitochondrial depolarization is reflected by
increase in the green/orange fluorescence intensity ratio (Figures 6). The ratio
of green/orange fluorescence of

JC-9 dye was measured on the A549 cells at

different time points after cells treatment at both pHs of 7.4 and 6.2 with the
pHLIP-coated liposomes containing 10% gA and on non-treated cells. Only
cells treated with the liposomes at low pH demonstrate increase of green/ orange
fluorescence ratio at 3-rd and 4-th days after the treatment indicating to the
mitochondria depolarization and cell apoptosis.
Discussion
The pHLIP-coated liposomes mimic highly efficient intracellular delivery
systems utilized by the viruses and pathogenic organ- isms[27-29], since pHLIP
at low pH performs function of the fusogenic peptides that brings membrane of
the liposome and a cell in close contact[16]. There are two case scenarios: i) the
liposome membrane fuse with the cellular membrane and transfer gramicidin
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conductive channel to the plasma membrane, or ii) the liposome enters a cell via
endocytosis, most probably, macropinocytosis, in the result of simultaneous
insertion of several pHLIP peptides into the plasma mem- brane, which can lead
to the plasma membrane raffling and blebbing and can trigger internalization of
the liposomes (Figure 7). In the latter case, the pHLIP-coated liposome will fuse
with the membrane of endosome at low pH. In both case scenarios, the gramicidin
channels will disrupt the balance of monovalent cations. At the same time, proton
pumps and sodium/potassium ion channels actively pump protons and sodium
ions from the cytoplasm to the extracellular space and potassium ions to the
cytoplasm. It takes time for complete equilibration of ions. Disturbance of ion
balance leads to the mitochondria depolarization, which is a signal of early
apoptosis. Interestingly, cells treated for 1 day at low pH with the pHLIP-coated
liposomes containing gramicidin, but then transferred to the media of normal
pH, demonstrated much less cytotoxicity compare with the cells growing at low
pH all the time.
We already demonstrated the pHLIP-mediated delivery and accumulation of
optical, PET and SPECT imaging agents, gold-nanoparticles and liposomes to
the acidic diseased tissue[10, 12, 13, 15].
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Figures

Figure 1. Schematic presentation of lipid bilayer of the pHLIP-coated
liposomes containing gramicidin A (gA) ion-conductive channels (a). Top view
of the gA channel showing conductive pore of 5 A˚ in the diameter (the atomic
coordinates of gA were visualized by the RasWin Molecular Graphics program using
1 MAG file from the Protein Data Bank).
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Figure 2. Biophysical characterization of liposomes containing gramicidin A. The
circular dichroism (a) and tryptophan fluorescence (b) of the DOPC liposomes
containing 10% gA were are shown (c–d) The DOPC liposomes containing 2% FITCDHPE lipids and containing no gA (red line) or 2% gA (blue line) in phosphate buffer
pH 8 or pH 3 were mixed with HCl or NaOH (dead time of mixing was 5 ms) to induce
transition from pH 8 to 3 (c) or transition from pH 3 to 8 (d), respectively. The changes
of FITC emission were observed in real time in the stopped- flow apparatus. The
baseline signal obtained by mixing of liposomes at pH 8 or pH 3 with buffer of the same
pH is shown by black lines.
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Figure 3. Inhibition of cell proliferation. HeLa, human cervix adenocarcinoma,
(a), M4A4, human breast ductal carcinoma, (b), A549, human lung carcinoma (c)
cells grown in standard media of pH 7.4 and adapted for low pH growth of 6.2 were
treated with the DOPC pHLIP- coated liposomes containing 10% gA and 5% pHLIP
for 18 hrs at pH 7.4 or 6.2 in DMEM followed by the replacement of media with
DMEM containing 10% FBS of the same pH as treatment or DMEM of pH7.4, 10%
FBS (blue columns). MTS assay was performed on 4-th day after the treatment.
(d) About 25,000 of A549 cells were seeded in an 8W10E 1 ECIS array in
DMEM at pH 6.2, next day cells were treated for 3 hrs with different
concentrations of the DOPC pHLIP-coated liposomes containing 10% gA and 5%
pHLIP liposomes in DMEM at pH 6.0 followed by addition an equal volume of
the DMEM containing 20% FBS at pH 6.2. The kinetics of inhibition of cell
proliferation was monitored by changes of capacitance within 5 days.
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Figure 4. Monitoring changes of intracellular pH. First, calibration curve was
established: A549 cells grown at pH6.2 were incubated with SNARF-5F
followed by washing with 50 mM phosphate/citric acid solution of pH 5.5, 6.0,
6.6, 7.2 and 7.5. To equilibrate extracellular and intracellular pH, the ionophore
nigericin was added to cells and the fluorescence spectra of SNARF-5F were
recorded (a). Ratio (595/640 nm) of SNARF-5F fluorescent signal was plotted
for each respective pH (black dots) and the linear fit was performed to establish
calibration curve (b). The fluorescence spectra of SNARF-5F was obtained on
A549 cells non-treated and treated with the DOPC pHLIP-coated liposomes
containing 10% gA and 5% pHLIP at pH 7.4 or 6.2 for 3 hrs followed by addition
an equal volume of the DMEM containing 20% FBS. The SNARF-5F emission
ratio of 595/640 nm was calculated and the corresponding intracellular pH was
obtained from the pH calibration curve (color dots on panel b).
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Figure 5. Monitoring changes of intracellular concentration of Na+. A549 cells
non-treated or treated for 1 day with the DOPC liposomes with 10% gramicidin
and 5% pHLIP at pH 6.2 and pH 7.4 were incubated with CoroNaTM Green next
and 3-rd days after the treatment followed by washing and imaging of cells. The
representative fluorescent and phase-contrast images of cells are shown (a–d).
The average per cell fluorescence intensity changes for control and treated cells
are shown on panel e.
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Figure 6. Mitochondria depolarization assay. The representative fluorescent JC9 images of A549 cells non-treated and treated with the DOPC pHLIP- coated
liposomes containing 10% gA and 5% pHLIP at pH 7.4 and 6.2 are shown (a–d).
Depolarization of mitochondria is characterized by changing color from yellow to
green of JC-9 fluorescence. The cells images were taken at excitation and emission
wavelengths centered at 490 nm and at 520 nm (green) or 540 nm and 580 nm
(yellow), respectively, at different days after cells treatment with the liposomes. The
changes in average ratio of green to yellow signals are shown on panel e.
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Figure 7. Schematic presentation of interactions of lipid bilayer of the pHLIPcoated liposomes containing gA with plasma membrane of a cell., which leads to the
transferring of gA channels (nano-pores) to the cellular membranes and disruption of
the monovalent cations balance (presentation of liposome in the endosome is schematic
and not in a scale).
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Supporting Information

a
b

Figure 1 SI. a) Size and Zeta Potential of pHLIP coated gA liposomes. Cryo-TEM
image of the DOPC pHLIP-coated liposomes containing 10% gA at 40,000x
magnification. b) Diameter and zeta potential of the DOPC pHLIP-coated liposomes
containing 10% gA, which were kept at 4℃ in 10 mM phosphate, 150 mM NaCl, pH
7.4 buffer, were monitored within 30 days.
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Figure 2 SI. Control experiments a) A549 cells adapted for low pH growth were
treated for 3 hrs with the DOPC pHLIP-coated liposomes containing 5% pHLIP and 010% gA in DMEM at pH 6.2 followed by the addition of an equal volume of the DMEM
with 20% FBS. MTS assay was performed on 4-th day after the treatment. b) about
3,000-4,000 A549 cells grown at pH 7.4 and 6.2, respectively, were treated with the
DOPC liposomes containing 10% gA, but no pHLIP for 18 hrs in DMEM at pH 7.4 or
6.2 followed by the replacement of media with DMEM containing 10% FBS. MTS
assay was performed on 4-th day after the treatment. c-d) about 3,00-4,000 A549 cells
grown at pH 7.4 and 6.2, respectively, were treated with the DOPC pHLIP-coated
liposomes containing 5% pHLIP, but no gA for 18 hrs in DMEM at pH 7.4 or 6.2
followed by the replacement of media with the DMEM containing 10% FBS. MTS assay
was performed on 4-th day after the treatment.

69

CHAPTER 3
Manuscript in Preparation 2016
Novel pHLIP® coated niasomes for diagnostic and therapy

Mohan C Pereira1, Monica Pianella2, Maria Carafa2, Carlotta Marianecci2, Oleg A
Andreev1, Yana K. Reshetnyak1*
1Physics

Department, University of Rhode Island, 2 Lippitt Rd., Kingston, RI, 02881,

USA
2

Department of Drug Chemistry and Technologies, Sapienza University of Rome,

Pzz.le, Aldo Moro 5, 00185, Rome, Italy

Corresponding author:
*

Yana K. Reshetnyak, Physics Department, University of Rhode Island, 2 Lippitt Rd.,

Kingston, RI, 02881, USA, Phone: (401)-874-2054, Fax: (401) 874-2060, E-mail:
reshetnyak@uri.edu

70

Abstract
Currently, nanomedicine is becoming very popular over conventional methods due to
the tunable physico-chemical properties used as successful therapeutic and diagnostic
agents to treat cancer and many other pathogenic conditions. However, the success of
these nanomedicines primarily relies on how specifically and efficiently they can target
pathological sites by minimizing undesirable effects. Here, we propose a novel class of
targeted nano- drug delivery system, which can be used as an effective nano-theranostic
for cancer. We formulated small, unilamillar niosomes using non-ionic surfactants
(SPAN20), cholesterol and pH(Low) Insertion Peptide (pHLIP), which is our targeting
moiety. pHLIP coated niosomes can sense the extracellular acidity of cancerous cells
and at low pH they can insert into the cellular membrane and successfully deliver
niosomes carrying hydrophobic or hydrophilic agents into the cells. Intravenous
injection of pHLIP-coated, noisome constructs show remarkable accumulation in mice
tumors compared to their pH- insensitive noisome constructs. Long circulation time and
uniform bio-distribution throughout the entire tumor and cells make them better delivery
systems for future clinical applications.

Keywords: pHLIP, niosomes, drug delivery, tumor acidity, targeted therapy,
nanomedicine
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Introduction
At present, scientists from various disciplines all over the world are involved in the
study of vesicles and other colloidal structures as carriers for passive or active targeting
to improve cancer therapy. However, most of the currently approved nanomedicinal
products for cancer therapy are non-targeted nanovectors that accumulate in tumor
tissues purely through the enhanced permeability and retention (EPR) effect and release
their payload in the extravascular tumor tissues for antitumor efficacy [1]. It is nearly
impossible to find a universal active targeting moiety for cancer as it is essentially
heterogeneous in nature[2, 3]. However, the extracelluar acidity of tumor cells has been
identified as a general property of cancerous cells and thus it can be used as a hallmark
to target tumors[4, 5]. Since a little over a decade ago when pH(Low) Insertion Peptide
(pHLIP) was discovered, this remarkable peptide has become a perfect candidate for
this purpose [6, 7]. This pH sensitive peptide stays in monomeric and unstructured form
in solution at normal pH in the absence of the lipid membrane. At the presence of the
lipid membrane, it binds to the surface, and, mainly, it stays as an unstructured
monomer. But at low pH, the Asp and Glu residues of the peptide protonate and enhance
its hydrophobicity causing it to insert into the cellular membrane by forming an apla helix [8, 9]. By appropriately modifying its N- or C- terminus, pHLIP can be used as a
bio-marker or it can be used to deliver membrane impermeable cargo into the cell by
utilizing the energy released during its insertion process[10-12]. It has also shed new
light on targeted nanomedicine since pHLIP has repeatedly proven its ability to sense
extracellular acidity over a wide variety of applications. Therefore, since the discovery
of pHLIP technology, various research groups have been applying this technology to
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form pH-sensitive nanoparticles based on lipid and inorganic materials[13-17]. In this
study we show how we can use pHLIP technology to formulate pH-sensitive, fusogenic
niosomes for cancer therapy.
Niosomes are closed bilayer structures formed by the self-assembly of non-ionic
amphiphiles in aqueous media. They were initially developed and patented by the
cosmetic company L’Oreal in the late 1970s [18], and the first commercial product of
“Niosome” antiaging cream was introduced to the market in the 1980s. They are
analogous to liposomes; like liposomes, niosomes can be multilamellar or unilamellar
vesicles, able to encapsulate both hydrophilic and lipophilic drugs. Non-ionic surfactant
vesicles are osmotically active, chemically stable, and have long shelf lives compared
to liposomes. Different types of surfactants have been proposed as starting materials
such as the Span® series, Tween® series and the Brij® series to prepare niosomes[19].
Physical and chemical properties of these surfactant families can be utilized to achieve
stable vesicular carriers, which have influence on fluidity, microviscosity and polarity
of bilayers [20-23].
Sorbitan esters (Spans®) are FDA approved for use in food processing and
pharmaceuticals [24]. They are safe, amphiphilic compounds derived from sorbitol
(i.e., a synthetic sweetener). Sorbitan esters are prepared by controlled dehydration
of sorbitol followed by lipase-catalyzed esterification of the resulting sorbitan.
Vesicles prepared by Span-series surfactants have been reported to be viable drug
carriers for different diseases and for different routes of administration (about 100
articles published in the last 5 years – data retrieved from Scopus).
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Span 20 consists of a fully saturated short alkyl chain (lauryl - C12). The single carbon
bonds in Span 20 allow the alkyl chain to pack tightly, resulting in a rigid membrane
for the assembled niosomes. According to this, Span 20 seems to assemble into smaller
and most stable niosomes compared to Span 40 and Span 60, which bear long saturated
acyl chains [palmityl (C-16) and stearyl (C-18) chains respectively] [25]. It was reported
that the length of alkyl chain is a crucial factor of permeability [26].Furthermore, Span
40 and 60 are in a gel state, compared with a liquid surfactant at room temperature. Such
features render Span 40- and Span 60-based niosomes less likely to leak the
encapsulated water-soluble drug molecules into their surrounding solution. In contrast,
Span 20-based niosomes are fluid at room temperature [27].

Materials and Methods
Materials
Sorbitan monolaurate (SPAN20) ,Cholesterol ≥ 99%, N-(2-Hydroxyethyl)piperazineN′-(2-ethanesulfonic acid) (HEPES) ≥ 99.5%(titration) & N-(1-Pyrenyl)maleimide
(Pyr-maleimide) were purchased from Sigma-Aldrich Inc (Atlanta, GA). 1,2-dioleoylsn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide]

(sodium

salt) (DSPE-maleimide), were obtained from Avanti Polar Lipids (Alabaster, AL).
Octadecyl Rhodamine B Chloride (R18) was purchased from Thermo Fisher Scientific
Inc.

The

wild

type

pH(Low)

Insertion

Peptide

(ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT) was prepared by solidphase peptide synthesis at C.S.Bio, CA and hereafter it will be referred as WT. All other
chemicals used were of the highest purity available and solvents were of spectroscopic
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grade. Water was purified through a Millipore(Bedford, MA) Milli-Q system and used
for all experiments.
Synthesis of DSPE-WT pHLIP & Pyr- WT pHLIP
DSPE-WT and Pyr-WT were synthesized by the covalent conjugation of malemide head
group of DSPE and Pyrene with the single cysteine residue at the N-terminus of WT .
The reaction was done with peptide to maleimide molar ratio 1.1:1 in Methanol and left
for overnight stirring at room temperature under argon. The existence of the product
was ensured by SELDI-TOF mass-spectrometry analysis.
SPAN-20 niosome preparation
10 mM stock solutions of SPAN20 and cholesterol were prepared by dissolving the
products in chloroform & methanol mixture of 3:1 (v/v). Solutions of the 43–50 mol%
of SPAN20, 50 mol% cholesterol mixed with 5 mol% DSPE-WT or Pyr-WT and 2
mol% fluorescent dye (R-18) were evaporated using a rotary evaporator at 60 °C
producing an even thin film for 1 hour, followed by the additional one hour evaporation
under a high vacuum to remove traces of organic solvents. This layer was hydrated in 2
mL ,10 mM, pH 7.4 HEPES buffer solution with or without 5 mM Ca2+. The resulting
solution was sonicated using the probe sonicator for 5 minutes at 60 degrees Celsius and
extruded 31 times through 200 nm filters. Niosomes were sterilized by filtering through
0.2 μm filter before the addition to cells. The concentration of SPAN20 was calculated
by measuring absorbance of R18 at 546 nm (ε = 104,126 M−1 cm−1) or pHLIP at 280
nm (ε = 13,940 M−1 cm−1 ) of the niosomes dissolved in methanol. Niosomes were
stored at 4°C.
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DLS and Zeta potential measurements
The size distribution of niosomes was measured by dynamic light scattering (DLS)
using a Malvern Zetasizer Nano ZS instrument with Malvern disposable cuvettes
(Malvern USA). The shelf life was monitored for a one month period in 10 mM HEPES
buffer at pH 7.4. In addition, size measurements were taken for 20 hours in 5% (v/v)
Serum medium at pH 7.4. The zeta potential was measured on the same instrument
using folded capillary cells from Malvern.
Cryo-electron microscopy
About 5 μL droplet of niosome solution was spread on a Lacey Formar/Carbon electron
microscopy grid and preserved in a frozen-hydrated state by a rapid freezing in liquid
ethane. The vitrification process was performed via FEI Vitrobot system with the setting
of a single blot of 3 sec, an offset of 1, and drain and wait time of 1 sec. Samples were
imaged using JEOL 2100 TEM with an accelerating voltage of 200 kV at magnifications
of 15,000× and 25,000×.
Cell lines
Lung carcinoma A549 and mouse mammary metastatic cancer 4T1 cell lines were
obtained from American Type Culture Collection (Manassas, VA). Cells were
authenticated, stored according to supplier’s instructions, and used within 3–4 months
after frozen aliquots resuscitations. Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) and Roswell Park Memorial Institute

Medium (RPMI)

supplemented with 10% (v/v) fetal bovine serum, 0.1% (v/v) of 10 μg/mL of
ciprofloxactin in a humidified atmosphere of 5% CO2 and 95% air at 37°C.
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Cell proliferation assays
About 3,000 of A549 and 4T1 cells were seeded in 96 well-plates at pH 7.4. The
following day, cells were treated for 2 hrs with various concentrations of pHLIP-coated
niosomes in respective serum free media at pH 7.4 and followed by the addition of an
equal volume of respective medium with 20% (v/v) FBS. For another set, the treatment
was completely removed after 2 hours and incubated again after adding fresh 10% (v/v)
FBS medium. Cells were grown until non-treated cells in control reached 80–90%
confluence. Cell viability was assessed by the colorimetric reagent (CellTiter 96
AQueousOne Solution Assay, Promega) of the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, which was added
for 1 hour to cells followed by measuring absorbance at 490 nm. All samples were
prepared in triplicate. Each experiment was repeated several times.
Measurement of cellular uptake
A549 and 4T1 cells in suspension were treated with R-18 labelled niosomes at low &
high pH for about 1 hour. After washing, cellular uptake of fluorescent niosomes was
assessed by the counting of fluorescent cells on a cellometer before and after adding
trypan blue. All data were normalized to the fluorescent intensity of 4T1 cells treated at
pH 7.8 with DSPE-pHLIP. After washing, another set of suspended cells were seeded
on collagen-coated dishes and the following day the light and fluorescent images were
taken for low pH treated cells for qualitative purpose.
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Tumor Mouse Models
All animal studies were conducted according to the animal protocol AN04-12-011
approved by the Institutional Animal Care and Use Committee at the University of
Rhode Island, in compliance with the principles and procedures outlined by NIH for the
Care and Use of Animals. 4T1 mammary tumors were established by subcutaneous
injection of 4T1 cells (1 × 106 cells/mL ,0.1 mL/flank) in the right flank of adult female
BALB/c mice (about 19–22 g weight) obtained from Harlan Laboratories.
Fluorescence Imaging of Organs
When 4T1 tumors reached 6-9 mm in diameter, they were intravenously injected with
different constructs of niosomes contained R18 (100 µL of 50 µM) via the tail vein. At
4 h, 24 h & 48 h from post injection the mice were euthanized and organs were harvested
and imaged using FX Kodak image station and mean fluorescence intensities of tumor
and organs was calculated using ImageJ software.

Imaging of Tumor Sections
Frozen tumor tissues were sectioned at a thickness of 5 μm using a Vibratome UltraPro
5000 Cryostat. Sections were mounted on microscope slides, dried in air, and washed
with deionized water. Tumor sections with the R18 contained pHLIP niosomes were
analyzed without further processing using Zeiss LSM 700 confocal module under DAPI
and Rhodamine channel at 20x magnification. Following fluorescence imaging, the
adjacent sections were then stained with hematoxylin and eosin (H&E) and imaged 20x
magnifications.
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Ca2+ Experiments: Cytotoxicity Assays and ECIS
About 3,000 4T1 cells were seeded in 96 well-plates at pH 7.4. The following day, cells
were treated for 3 hrs with various concentrations of Pyr-WT-coated niosomes
containing 5 mM Ca2+ in RPMI serum free media at pH 7.4 and pH 6.5. After 3h, the
treatment was completely removed and incubated again after adding fresh 10% (v/v)
FBS medium at pH 7.4. Cells were grown until non-treated cells in control reached 80–
90% confluence. Control assay was run with the treatment niosomes without Pyr-WT.
Cell viability was assessed by the colorimetric reagent (CellTiter 96 AQueousOne
Solution

Assay,

Promega)

of

the

MTS

(3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, which was added
for 1 hour to cells followed by measuring absorbance at 490 nm. All samples were
prepared in triplicate. Each experiment was repeated several times.

The kinetics of inhibition of proliferation of 4T1 cells treated with pyr-WT coated
niosomes containing 5 mM Ca2+ HEPES physiological medium was monitored by
changes of capacitance measured at AC frequencies using the ECIS (electric cellsubstrate impedance sensing) technique. The capacitance varies in a linear fashion with
the fractional cell coverage of the bottom of a special chamber coated with thin film
gold electrodes connect to the ECIS electronics[28]. When cells were shrinking and
dying after treatment with the construct the capacitance was increasing. The cell death
starts within 30 minutes after the treatment.
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Ca2+ Experiments: In Vivo Studies
4T1 mammary tumors were established by subcutaneous injection of 4T1 cells (1 × 106
cells/mL ,0.1 mL/flank) in both flanks for the IT injection group and only in the right
flank for the IV injection group of adult female BALB/c mice (about 19–22 g weight)
obtained from Harlan Laboratories. When tumors became visible, 50 uL and 150 µL,
2.5 mM Pyr-WT niosomes with 5 mM Ca2+ were injected into the mice directly into the
tumor and via the tail vein respectively. The injections were performed for three
consecutive days for both IT and IV groups. The control was not given any injection.
On the 5th day from the initial injection, mice were euthanized and tumors were
harvested and weighed.
Results
We were able to formulate very stable niosomes with the average hydrodynamic size of
~80 nm (Fig. 1, Table 1) and they showed a prolonged shelf life at 4 °C in 10 mM
HEPES buffer at pH7.4 (SI .Fig 1). At this pH, anionic pHLIP adds electrostatic
repulsion to the niosomes. In addition to that, 5% pHLIP, which is more than enough to
cover the noisome surface completely, could act as grafted polymers, sticking out into
the solution. When the particles come close enough to overlap, the local increase of
polymer concentration leads to an osmotic pressure, causing a repulsive force which
further minimizes inter-niosomal fusion. Due to these effects, we observed high zeta
potential for the niosomes showing high stability over an extended period at 4 °C.
Cell proliferation assays done with 4T1 & A549 cells confirmed that DSPE-WT pHLIP
and Pyr-WT pHLIP-coated niosomes do not show any toxicity for the surfactant
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concentration up to 1 mM ( SI Fig 2). The cellular uptake of pHLIP-coated niosomes
were monitored using R18 fluorescence. It is evident that at low pH, significantly high
cellular uptake occurs compared to cells treated at high pH (Fig.a, b, c & d) . After
adding trypan blue, the fluorescent signal of R18 was remeasured for each pH and cell
line to ensure the signal came only from the R18 within the cell. This data also confirms
that at low pH there is higher uptake of pHLIP labelled niosomes (Fig 2, SI.Fig 3).
Fluorescent images taken at low pH for both constructs and for both cell lines clearly
show the distribution of R18-labeled niosomes over the cellular membranes and
throughout the cell (Fig.2 a,b,c & d). This data confirms that the pH-dependent and
mediated cellular uptake of pHLIP coated niosomes.
In-vivo kinetics (Fig 3) show a higher accumulation of both the DSPE-WT and Pyr-WT
niosomes in tumor sites 24 hours post injection compared to other organs. The R18
intensity profile for the same organs (Fig 4 a,b) were analyzed after 24 hours from I.V.
administration of DSPE-PEG, DSPE-WT pHLIP, DSPE-6K, Pyr-WT and Pyr-6K
constructs. Here, 6K stands for the pH independent counter-part of WT pHLIP where
all D(Asp) and E(Glu) residues were replaced by K(Lys). DSPE-PEG, DSPE- 6K, and
Pyr- 6K show accumulation in the tumor site purely due to the EPR effect. However,
DSPE- WT and Pyr- WT show about a two-fold accumulation compared to the other
three constructs. Tumor sections taken from the interior of the tumors (Fig. 5) clearly
show that both niosomes coated with DSPE –WT and Pyr-WT distributed throughout
the tumor and fused with extra and intra cellular membranes more evenly.
We were able to use Pyr-WT coated niosomes to deliver 5 mM Ca2+ ions to 4T1 cancer
cells and tumors as a novel therapeutic agent. Cyto-toxicity assays done with niosomes
81

with and without Pyr-WT shows that at low pH only the Pyr-WT coated niosomes can
inhibit the cell proliferation in a concentrated dependent manner (Fig.6). Kinetics data
(ECIS) show that this cell death starts within 30 minutes of treatment(Fig.7).
After 3 consecutive days of intra-tumoral injections of Pyr-WT niosomes containing 5
mM Ca2+ , it was seen to significantly suppress the growth of tumors compared to its
control on the 5th day. The IV injections also show that Pyr-WT coated niosomes with
5 mM Ca2+ could suppress tumor growth (Fig 8).
Discussion
The DSPE-WT and Pyr- WT coated niosomes, follow a closely similar mechanism
utilized by viruses and pathogenic organisms to enter into cells [14, 15, 29, 30] . At low
pH, pHLIP behaves as a fusogenic peptide to bring the noisome membrane and the
extracellular membrane in close contact. There are two main possibilities for this
cellular entry. Either the noisomes fuse directly with the extracellular membrane or they
can be taken up into the cell via an endocytotic path, or more favorably, via
micropinocytosis due to several simultaneous pHLIPs inserted into the membrane.
Niosomes, which are internalized into the cell via endocytosis, will further fuse with the
endosome membrane at low pH. In either case, niosomes modified with lipophilic or
hydrophilic drugs can effectively enter into the cells in a pH-dependent manner.
In-vitro studies confirm that niosomes distribute throughout the cell and the cellular
uptake is governed by the extracellular acidicity of the cancerous cells. In vivo results
show that the pHLIP coated niosomes possess long circulation half-life because of their
stability, small size, and stealth properties which help niosomes to accumulate more in
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tumor sites through the EPR effect. The tumor sections also show that the niosomes can
distribute throughout the tumor. In addition to this, low toxicity, prolonged shelf life,
and low manufacturing cost also make niosomes ideal targeted, drug delivery systems
for carrying therapeutics and diagnostics to cancer.
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Tables

Construct

45%SPAN20+5%DSPEWT+50%Cholesterol
45%SPAN20+5% PyrWT+50%Cholesterol

Avg.
Diameter
(nm)
84.3 ± 0.9

Zeta Potential
(mV)

PDI

-35.4 ± 2.3

0.19 ± 0.01

78.5 ± 0.5

-31.3 ± 1.7

0.25 ± 0.01

Table 1. Niosome Characterization Data Average hydrodynamic diameter and zeta
potential of the SPAN20 niosomes containing 5% of DSPE-WT & Pyr-WT coating at
pH 7.4 HEPES buffer.
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Figures

Figure 1: Cryo -TEM Cryogenic TEM image of the a.) DSPE-WT and b.) Pyr-WT
coated SPAN20 niosomes, The images are taken at HV=200.0 kV and at 25,000x
magnification
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Before Trypan
After Trypan

Figure 2. Cellular Uptake of R18 Niosomes Fig. 2 a-d : 4T1 and A549 cells uptake of
DSPE-WT and Pyr-WT coated SPAN20 niosomes at low pH at 40x magnification Fig.
2 e & f: R18 fluorescent intensity per cell at high and low pH for two cell lines for before
and after adding trypan blue. The normalization is done by the intensity of 4T1 cells at
pH 7.8, treated with DSPE-WT (before adding trypan).
89

Figure 3: In-Vivo Kinetics Time-dependent distribution of DSPE-WT and Pyr-WT
coated R18 SPAN20 niosomes in tumor, muscle, kidney and liver at 4 h , 24 h and 48 h
from post-injection. The net, absolute fluorescent intensity of R18 is shown.
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b

Figure 4: In-Vivo Imaging 24 h Fig.4 a: Absolute net mean R18 fluorescent intensity
by tumor, muscle, kidney and liver for five constructs after 24 h from I.V. injection.
DSPE-6K and Pyr-6K constructs are the controls. ∗ 𝑝 ≤ 0.05 𝑎𝑛𝑑 ∗∗ 𝑝 ≤ 0.005
Fig.4 b: Distribution of different pHLIP niosomes over tumor, muscle, kidney and
liver.
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Figure 5: Tumor Sections Tumor sections with the R18 contained pHLIP niosomes
were analyzed without further processing using Zeiss LSM 700 confocal module under
DAPI and Rhodamine channel at 20x magnification.
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Figure 6: Delivery of Ca2+ into Cancer Cells using Pyr-WT coated niosomes.
4T1 cells grown in standard media of pH 7.4 were treated with the pyr-pHLIP
coated niosomes and noisome alone containing 5 mM Ca2+ HEPES buffer for 3 hours at
pH 7.4 and 6.5. After 2 hours the treatment was completely removed and the
replacement of media with RPMI medium containing 10% FBS of the pH 7.4 .
MTS assay was performed on 2nd day after the treatment.
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Figure 7. ECIS Assay. About 25,000 of 4T1cells were seeded in an 8W10E 1
ECIS array in RPMI at pH 7.4, next day cells were treated for 3 hrs with pyrpHLIP-coated niosomes containing 5 mM Ca2+ HEPES physiological medium.
Control was treated with the 5 mM Ca2+ HEPES physiological medium. After 3
hours the treatment was completely removed and fresh RPMI medium at 7.4 was
added, The kinetics of inhibition of cell proliferation was monitored by changes of
capacitance within 2 days.
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Figure 8. Delivery of Ca2+ into tumors using Pyr-WT coated niosomes. 50 µL and
150 µL, 2.5 mM Pyr-WT niosomes with 5 mM Ca2+ were injected to mice directly into
the tumor and via tail vein respectively. The injections were performed three
consecutive days for both IT and IV groups. Control was not given any injection. The
5th day from the initial injection, mice were euthanized and tumors were harvested and
weighed.
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Supplementary Information

4T1
Construct
DSPE-WT
Pyr-WT

pH 5.5
pH 5.5

DSPE-WT
pH 7.8
5.72405E-17
-

Pyr-WT
pH 7.8
3.188E-131

A549
DSPE-WT
Pyr-WT
pH 7.8
pH 7.8
4.4094E-118
2.158E-176

Table 1 SI. p-values for Cellular uptake after adding trypan blue for Fig 2 (e,f)

DSPE-PEG
n=3
Tumor
1108 ± 28
Muscle
209 ± 29
Kidney
233 ± 22
Liver
449 ± 42

DSPE-WT
n=3
2015 ± 96
363 ± 25
399 ± 38
1100 ± 141

DSPE-6K
n=3
859 ± 104
63 ± 11
115 ± 16
315 ± 47

Pyr-WT
n=3
2409 ± 334
1173 ± 384
255 ± 22
893 ± 195

Pyr-6K
n=3
762 ± 102
82 ± 17
1145 ± 15
379 ± 134

Table 2 SI. In-Vivo Data for 24 h post injection. R-18 Fluorescence Intensities for
different constructs of SPAN20 niosomes for 24 hour post injection time point
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a.) Tumor

Construct

DSPE-PEG

DSPE-WT

DSPE-6K

Pyr-WT

DSPE-WT
DSPE-6K
Pyr-WT
Pyr-6K

0.011110833
0.004084324
0.085369064
0.14182076

0.005930916
0.440380217
0.002074218

0.054168579
0.951904631

0.053471726

Construct

DSPE-PEG

DSPE-WT

DSPE-6K

Pyr-WT

DSPE-WT

0.031788716

-

-

-

DSPE-6K

0.041197513

0.004241393

-

-

Pyr-WT

0.176471875

0.227173591

0.142288157

-

Pyr-6K

0.062865506

0.002848675

0.3722053

0.148297054

b.) Muscle

c.) Kidney
Construct

DSPE-PEG

DSPE-WT

DSPE-6K

Pyr-WT

DSPE-WT

0.048451793

-

-

-

DSPE-6K

0.028163836

0.01483796

-

-

Pyr-WT

0.593468874

0.069538949

0.018131454

-

Pyr-6K

0.035691411

0.015410281

0.766032839

0.022063672

d.) Liver
Construct

DSPE-PEG

DSPE-WT

DSPE-6K

Pyr-WT

DSPE-WT

0.05391268

-

-

-

DSPE-6K

0.15888622

0.034671751

-

-

Pyr-WT

0.200977834

0.526664862

0.130616957

-

Pyr-6K

0.950470866

0.070237338

0.625925234

0.221457553

Table 3 SI. p-values corresponds to Table 2
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Figure 1 SI. Diameter and zeta potential of the pHLIP-coated nosomes containing,
which were kept at 4 0C in HEPES pH 7.4 buffer and HEPES buffer with 5% FBS
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Figure 2 SI.Cyto-toxicity Assays. 3000 cells at normal pHs were seeded in 96 well
plates. Following day, plates were treated with different concentrations of niosome
formulations in serum free media and incubated for 2 hours. For each treatment, after 2
hours the medium was removed and added fresh medium. For another set equal volume
of medium with 20% FBS added. When cell confluency reached 80-90% MTS assay
was done.
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Figure 3 SI. Cellular uptake of R-18 niosomes. 4T1 & A549 cells in suspension were
treated with R-18 labelled niosomes at low & high pH. Cellular uptake of fluorescent
niosomes was assessed by counting of fluorescent cells on a cellometer.
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